(I NOVARTI S
`
`e:,
`LUCENTIS
`AAN BIZUMAB
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Draft Minutes Agenda
`
`Meeting Date: Sept. 3 2012
`Meeting Notes Date:
`Author:
`Room: WSJ-210.07.24
`Dial-in:
`
`Team Members: (✓ = Present, !..:= part-time)
`
`Team Members: (✓ = Present, • = part-time)
`
`. - - { Formatted: <:,entered, Indent: Left: ·0.19 cm
`
`Topic/Situation: Project update
`
`Pre-reads
`
`Discussion
`
`TRD Subteam Meeting Aoenda: Date of Meeting: Septembef 3. 2012
`
`1 of 7
`
`( Formatt(KI: lndent: Left: 0 cm
`
`~ Fonnatted: Foot: Italic
`Formatted: Foot: Italic
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2084.001
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`e:,
`LUCENTIS
`AAN BIZUMAB
`Business Use Only
`
`Lucentis PFS (RFB002)
`
`TRD SubTeam meeting
`
`Draft Minutes Agenda
`
`Meeting Date: Sept. 3 2012
`Meeting Notes Date:
`Author:
`Room: WSJ-210.07.24
`Dial-in:
`
`Team Members: (✓ = Present, !..:= part-time)
`
`Team Members: (✓ = Present, • = part-time)
`
`. - - { Formatted: <:,entered, Indent: Left: ·0.19 cm
`
`Topic/Situation: Project update
`
`Pre-reads
`
`Discussion
`
`TRD Subteam Meeting Aoenda: Date of Meeting: Septembef 3. 2012
`
`1 of 7
`
`( Formatt(KI: lndent: Left: 0 cm
`
`~ Fonnatted: Foot: Italic
`Formatted: Foot: Italic
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2084.001
`Regeneron v. Novartis, IPR2021 -00816
`
`
`
`Closed
`
`When
`
`Lead: ·
`
`Pre-reads
`
`-- _,
`..L
`
`Open
`
`Who
`
`Achievements
`
`Issues
`What
`
`Topic/Situation
`
`I
`
`Discussion
`
`__..---{ Formatted: Font: Italic
`
`•- { Formatted: Left
`
`x::::: Formatted: Font: (Default) Aria~ 10 J:t
`-- Fi~ld Code Changed
`
`Formatted: Right: O cm, Space Before: Opt, Line Sl)adng:
`single, Don't adjust space between Ulm and Asi.cn text., DcWl't
`ad),st space between Asian text and numbErs, Tab stops: lfot
`at 16.98 cm
`
`- Formatted: Underline
`~ Formatted: No ouuets Of rum1>er1ng
`~
`
`Formatted: English (lklitcd States)
`Formatted: Numbered + Level: I + Numberino Style: I, 2,
`3, ... + Start at: I + Alignment: left + Aligr>ed at 0 cm +
`Tab after: 0.63 cm + Indent at: 0.63 cm
`Formatted: English (united States)
`Formatted: English (united States)
`
`TRD Subteam Meeting Aoenda: Date of Meeting: Septembef 3. 2012
`
`2 of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2084.002
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Formatted: lnde,,t: Left: 0.16 an, Hanging: 0.48 cm, No
`bulets er numbering
`Fonnatted: Foot: '"1glish (Unite<J Stoles)
`
`Formatted: Font:
`Formatted: Bulleted + LeVEI: I + Aligned at: 0.63 cm + Tab
`after: 1.27 cm + Indent at: 1.27 cm
`formatted: Foot: English (United States)
`
`Ii
`
`(
`
`I
`
`/,
`
`~
`~
`
`j
`
`'11
`
`1
`
`Formatted: Foot:
`Formatted: Inde<1t: Left: 0.63 an, No bullets er numbering
`Formatted: No bullets o, numbe~ng
`/ I/JJ! Formatted: Ust Paragraph, Bolleted + Level : 1 + Aligned at:
`0.63 cm + Irdent at: 1.27 c:m
`if. Formatted: English (Ullted States)
`Formatted: Foot: (Default) Arial, 10 JC(
`Formatted: English (Ulited States)
`Formatted: Bulleted + LeVEI: I + Aligned at: 0.63 cm + Tab
`after: 1.27 cm + Indent at: 1.27 cm
`Formatted: English (Ulited States)
`Formatted: English (Ulited States)
`Formatted: Font:
`.I Formattee1: Ul1<Jel'llne
`I Formatted: No underline
`'1 Formatted: No underline
`Formatted: English (Ulited States)
`Formatted: Bulleted + LeVEI: I + Aligned at: 0.63 cm +
`lnclcnt ot: 1.27 cm
`Formatted: Bulleted + LeVEI: 2 + Aligned at: 1.9cm+
`Indent at: 2.54 cm
`Formatteel: English (Ulited States)
`Formatted: English (Ulited States)
`Formatted: Bulleted + LeVEI: I + Aligned at: 0.63 cm +
`Indent at: 1.27 cm
`Formatted: English (Ullted States)
`
`11
`~~ Formatted: Bulleted + LeVEI: I + Aligned at: 0.63 cm +
`~ Formatted: List Paragraph, Bolleted + Level : I + Aligned at:
`
`Formatted: SuUeted .... Level: 2 .,. AJignetl ~t: 1.9cm..-
`Indent at: 2.54 cm
`Formatted: English (Ulited States)
`
`Indent at: 1.27 cm
`Formatted: Foot: (Default) Arial, 10 JC(
`
`1.9cm + Indent at: 2.S4 cm
`Formatted: English (Ulited States)
`Formatted: Bulleted + LeVEI: I + Aligned at: 0.63 cm +
`Indent at: 1.27 cm
`
`TRD Subteam Meeting Aoenda: Date of Meeting: Septembef 3. 2012
`
`3of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2084.003
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Achievements
`
`Issues
`What
`
`Actions
`What
`
`-
`
`Topic/Situation
`
`Ooen
`
`Who
`
`-
`
`-
`
`Closed
`
`When
`
`Lead:
`
`Pre-reads
`
`I
`
`Achievements_
`
`Issues
`What
`
`Actions
`What
`
`O n
`
`Closed
`
`Who
`
`When
`
`TRD Subteam Meeting Aoenda: Date of Meeting; Septembef 3. 2012
`
`4 of 7
`
`~
`~
`
`Formatted: EngliSh (Ullted States)
`Formatted: Bulleted + Levtl: 2 + Aligned at: l.9cm+
`Indent al: 2.54 cm
`Formatted: No bullets or numbering
`Formatted: English (Ulited States)
`Formatted: English (Ulited States)
`
`Formatted: English (Ulited States)
`Formatted: English (Ulited States)
`Formatted: Bulleied + Levtl: I + Aligned at: 0.63 cm +
`Indent ot: 1.27 cm
`Formatted: English (Ulited States)
`Formatted: English (Ulited States)
`Formatted: Bulleted + Levtl: 2 + Aligned at: 1.9 cm+
`[l'~ lll et: 2.54 <:I'll
`
`Formatted: Englifh (l.hited Stat~)
`
`Formatted: EngliSh (Ulited States)
`Formatted: English (Ulited States)
`Formatted: English (Ulited States)
`Formatted: lndeot: Left: 2.54 an, No bulletS er numbering
`Formatted: lndet1t: Left: 0,63 an, No bullets er ,lumbering
`Formatted: Font: ltalk
`Formatted: Font: Bold, Italic
`Formatted: Font: Italic
`Formatted: English (Ulited States)
`Formatted: Bulleted + Levtl: I + Aligned at: 0.63 cm +
`Indent al: 1.27 cm
`Formatted: English (Ulited States)
`Formatted: English (Ullted States)
`Formatted: EngllSh (Ullted States)
`Formatted: Englr>h (l.ktrted States)
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2084.004
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Topic/Situation
`
`Discussion
`
`Achievements
`
`Issues
`What
`
`Actions
`_What
`
`Topic/Situation
`
`l Discussion
`
`Achievements
`
`Issues
`What
`
`Actions
`What
`
`Lead
`
`Pre-reads
`
`Open
`
`Closed
`
`-
`
`_ Who
`
`When
`
`Lead:
`
`Pre-reads
`
`Open
`
`W ho
`
`Closed
`
`When
`
`TRD Subteam Meeting Aoenda: Date of Meeting: Septembef 3. 2012
`
`5of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2084.005
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Topic/Situation
`
`Discussion
`
`Achievements
`
`Issues
`What
`
`Actions
`What
`
`Oisci line/ Line function :
`
`Topic/Situation
`
`Achievements
`
`Issues
`What
`
`Actions
`What
`
`Lead:
`
`Pre-reads
`
`Closed
`
`When
`
`Lead
`
`Pre-reads
`
`0 n
`
`Open
`
`Who
`
`Closed
`
`When
`
`TRD Subteam Meeting Aoenda: Date of Meeting: Septembef 3. 2012
`
`6of 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2084.006
`Regeneron v. Novartis, IPR2021-00816
`
`
`
`Consolidated Action Plan
`
`What
`
`■
`
`Who
`
`When ---
`--
`---
`
`Code --
`
`TRD Subteam Meeting Ag,nda: Date of Meeting: September 3, 2012
`
`7 cf, 7
`
`CONTAINS CONFIDENTIAL BUSINESS INFORMATION, SUBJECT TO PROTECTIVE ORDER
`Novartis Exhibit 2084.007
`Regeneron v. Novartis, IPR2021-00816
`
`
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
